Boston Scientific Corp (BSX.N)
12 Dec 2013
|Market Cap (Mil.):||$14,927.78|
|Shares Outstanding (Mil.):||1,335.22|
- An advisory panel of medical experts voted on Wednesday to recommend that U.S. health regulators approve an experimental stroke-prevention device made by Boston Scientific Corp
Dec 11 - An advisory panel of medical experts voted on Wednesday to recommend that U.S. health regulators approve an experimental stroke-prevention device made by Boston Scientific Corp
* Says US FDA advisory committee votes 13-1 that benefits of Watchman anti-stroke device outweigh risks
- U.S. Food and Drug Administration staff reviewing data on Boston Scientific Corp's novel anti-stroke device highlighted the implant's failure to meet a key goal for effectiveness in a recent study but said on Monday that other data must be weighed in deciding whether it should be approved.
Dec 9 - Boston Scientific Corp's anti-stroke device did not meet one measure of success in a clinical study of the implant, but other data must be considered when determining overall safety and effectiveness, staff members of the U.S. Food and Drug Administration stressed on Monday.
CHICAGO, Dec 9 - Boston Scientific Corp : * FDA emphasizes Boston Scientific anti-stroke device did not meet
WASHINGTON, Nov 5 - The U.S. Supreme Court on Tuesday heard arguments in a case of warring legal doctrines raised by a heart pacemaker patent fight between giant medical devices company Medtronic Inc and privately owned Mirowski Family Ventures LLC.
Oct 24 - Boston Scientific Corp, which is in the midst of an attempted turnaround, reported weak sales of its heart stents and provided a disappointing fourth-quarter company sales forecast, sending its shares almost 7 percent lower on Thursday.
Oct 23 - Medical device maker Boston Scientific Corp plans to cut up to 1,500 jobs in its latest restructuring effort that aims to save $150 million to $200 million in operating expenses by the end of 2015, the company announced in a regulatory filing.
WASHINGTON - Boston Scientific Corp agreed to pay $30 million to settle allegations that the Guidant unit it acquired in 2006 knowingly sold defective heart devices implanted in Medicare patients, the U.S. Justice Department said on Thursday.